SCIENTIFIC, TECHNOLOGICAL AND ORGANIZATIONAL DECISIONS TO INCREASE EFFICIENCY AND TIMELINESS OF HEART TRANSPLANTATION
https://doi.org/10.15825/1995-1191-2014-3-14-22
Abstract
Aim. To analyze approaches to pretransplant treatment of potential heart recipients and heart donation criteria, directed to reduction of mortality on a waiting list and to increase of volume and effi ciency of heart transplantations.
Methods and results. Data on 285 HT recipients (performed in 2008–2013) were analyzed. The analysis and comparison of patients with circulatory support before heart transplantation, using «high-risk» donors (aged over 40 years, with left ventricular hypertrophy ≥ 1.5 cm, after cardiopulmonary resuscitation, with the reduced systolic function of the left ventricle (< 40%), with potentially repair pathology of the heart valve and coronary arteries); to high risk recipients (over 60 years, with high pulmonary hypertension and earlier operated) were made.
Conclusion. The proposed scientifi c, technological and organizational solutions made possible the timely performance of heart transplantation to patients with an inevitable lethal outcome as a result of heart failure.
About the Authors
S. V. Gautier
V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation
I.M. Sechenov First Moscow State Medical University, Department of transplantology and artifi cial organs, Moscow, Russian Federation
academician of the RAS, professor, Director of V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs, Moscow, Russian Federation; Head of Department of Transplantology and artifi cial organs, I.M. Sechenov First
Moscow State Medical University, Moscow, Russian Federation
V. N. Poptsov
V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation
prof., Head of Anesthesia and Intensive Care Department at the same center
R. Sh. Saitgareev
V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation
I.M. Sechenov First Moscow State Medical University, Department of transplantology and artifi cial organs, Moscow, Russian Federation
prof., Head of Cardiac Surgery and Heart – Lung Transplantation Department at the same center
D. V. Shumakov
V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation
prof., corresponding member of the RAS, Head of Cardiac Surgery, circulatory support complex arrhythmias and pacing Department at the same center
V. M. Zakharevich
V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation
I.M. Sechenov First Moscow State Medical University, Department of transplantology and artifi cial organs, Moscow, Russian Federation
physician-heart surgeon of cardiac surgery № 2 Division at the same center; prof., Department of Transplantology and artifi cial organs, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
E. A. Spirina
V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation
physician anesthesiologist of anaestesiology and intensive therapy Department at the same center
References
1. Organ Donation and Transplantation Activities 2010. 2011; Availablefrom: http://www.transplant-observatory. org.
2. Hertz MI. The Registry of the International Society for Heart and Lung Transplantation-Introduction to the 2012 annual reports: new leadership, same vision. J Heart Lung Transplant. 2012 Oct; 31 (10): 1045–1051.
3. Barth E, Durand M, Heylbroeck C et al. Rossi-Blancher M. Extracorporeal life support as a bridge to high-urgency heart transplantation. Clin Transplant. 2012; 26 (3): 484–488.
4. Loisance D, Hillion ML, Deleuze P et al. Extracorporeal circulation with membrane oxygenation as a bridge to transplantation in cardiac surgical patients. Transplant Proc. 1987; 19 (5): 3786–3788.
5. Готье СВ, Попцов ВН, Спирина ЕА. Экстракорпоральная мембранная оксигенация в кардиохирургии и трансплантологии. М.: Триада, 2013: 160–174. Gautier SV, Poptsov VN, Spirina EA. Ekstrakorporal'naya membrannaya oksigenatsiya v kardiokhirurgii i transplantologii. M.: Triada, 2013: 160–174.
6. Goland S, Czer LS, Kass RM et al. Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool. J Am Coll Cardiol. 2008; 51 (12): 1214–1220.
7. Quader MA, Wolfe LG, Kasirajan VK. Does cardiopulmonary arrest and resuscitation of heart donors ported inferior outcomes in heart transplantation recipients? J Heart Lung Transpl. 2013; 32: S94.
8. Aziz S, Soine LA, Lewis SL et al. Donor left ventricular hypertrophy increases risk for early graft failure. Transpl Int. 1997; 10: 446–450.
9. Marelli D, Laks H, Fazio D, Moore S, Moriguchi J, Kobashigawa J. The use of donor hearts with left ventricular hypertrophy. J Heart Lung Transplant. 2000; 19: 496–503.
10. Yang HY, Lin CY, Tsai YT, Lee CY, Tsai CS. Experience of heart transplantation from hemodynamically unstable brain-dead donors with extracorporeal support. Clin Transplant. 2012; 26 (5): 792–796.
11. Lundgren J, Algotsson L, Kornhall B, Rådegran G. Preoperative pulmonary hypertension and its impact on survival after heart transplantation. Scand Cardiovasc J.2014; 48 (1): 47–58.
12. Gude E, Simonsen S, Geiran OR, Fiane AE, Gullestad L, Arora S et al. Pulmonary hypertension in heart transplantation: discrepant prognostic impact of pre-operative compared with 1-year post-operative right heart hemodynamics. J Heart Lung Transplant. 2010 Feb; 29 (2): 216–223.
13. Chiu P, Russo MJ, Davies RR, Addonizio LJ, Richmond ME, Chen JM. What is high risk? Redefi ning elevated pulmonary vascular resistance index in pediatric heart transplantation. J Heart Lung Transplant. 2012; 1:61–66.
14. Maruszewski M, Zakliczyński M, Przybylski R, Kucewicz-Czech E, Zembala M. Use of sildenafi l in heart transplant recipients with pulmonary hypertension may prevent right heart failure. Transplant Proc. 2007; 39 (9): 2850–2852.
15. Lund LH, Edwards LB, Kucheryavaya AY et al. The registry of the International Society for Heart and Lung Transplantation: Thirtieth offi cial adult heart transplant report – 2013. J heart Lung Transplant. 2013; 32: 951– 964.
Review
For citations:
Gautier S.V., Poptsov V.N., Saitgareev R.Sh., Shumakov D.V., Zakharevich V.M., Spirina E.A. SCIENTIFIC, TECHNOLOGICAL AND ORGANIZATIONAL DECISIONS TO INCREASE EFFICIENCY AND TIMELINESS OF HEART TRANSPLANTATION. Russian Journal of Transplantology and Artificial Organs. 2014;16(3):14-22. (In Russ.) https://doi.org/10.15825/1995-1191-2014-3-14-22
Views:
1509
Email this article 